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Abstract
Metaplastic breast carcinomas are reported to harbour epidermal growth factor receptor
(EGFR) overexpression in up to 80% of the cases, but EGFR gene amplification is the
underlying genetic mechanism in around one-third of these. In this study, EGFR gene
amplification as defined by chromogenic in situ hybridization and protein overexpression
was examined in a cohort of 47 metaplastic breast carcinomas. Furthermore, the presence
of activating EGFR mutations in exons 18, 19, 20, and 21 was investigated. Thirty-two cases
showed EGFR overexpression and of these, 11 (34%) harboured EGFR gene amplification.
In addition, EGFR amplification showed a statistically significant association with EGFR
overexpression (p < 0.0094) and was restricted to carcinomas with homologous metaplasia.
Ten cases, five with and five without EGFR amplification, were subjected to microarray-
based CGH, which demonstrated that EGFR copy number gain may occur by amplification
of a discrete genomic region or by gains of the short arm of chromosome 7 with a
breakpoint near the EGFR gene locus, the minimal region of amplification mapping to
EGFR, LANCL2, and SEC61G. No activating EGFR mutations were identified, suggesting
that this is unlikely to be a common alternative underlying genetic mechanism for EGFR
expression in metaplastic breast carcinomas. Given that metaplastic breast carcinomas are
resistant to conventional chemotherapy or hormone therapy regimens and that tumours
with EGFR amplification are reported to be sensitive to EGFR tyrosine kinase inhibitors,
these findings indicate that further studies are warranted to explore EGFR tyrosine kinase
inhibitors as potential therapeutic agents for metaplastic breast carcinomas harbouring
amplification of 7p11.2.
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Introduction
The gene for the epidermal growth factor recep-
tor (EGFR) maps to 7p11.2–p12 and comprises 28
exons [1], which encode a protein containing an
extracellular ligand-binding domain, a transmembrane
domain, and a tyrosine kinase domain [1]. EGFR
was the first tyrosine kinase transmembrane recep-
tor to be directly linked with human cancer [1]. In
recent years, EGFR tyrosine kinase inhibitors have
received FDA approval and are currently being tested
in patients with lung, gastric, and breast cancer [2].
There appear to be distinct mechanisms for EGFR
activation in different types of human neoplasms.
EGFR gene amplification has been described in oligo-
dendrogliomas [3], glioblastomas [4], lung carcinomas
[2,5,6], gastric carcinomas [7], and, recently, breast
carcinomas [8–11]. On the other hand, EGFR activat-
ing mutations have proven to be present in a subset
of central nervous system tumours and lung cancer
[1,5,12], but are remarkably rare in breast cancer cell
lines and human breast cancer samples [8].
Metaplastic breast carcinomas (MBCs) account for
up to 3.7% of all breast carcinomas. We and others
have demonstrated that these neoplasms consistently
harbour a basal/myoepithelial phenotype [13–19],
Copyright  2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
www.pathsoc.org.uk
JS Reis-Filho et al
therefore suggesting that they may be part of the mor-
phological spectrum of ‘basal-like’ breast carcinomas.
Our group and others have shown that MBCs con-
sistently overexpress EGFR but usually lack HER2
overexpression and amplification [11,13,20,21]. In a
preliminary study, we demonstrated that in 37% of
EGFR 3+ MBCs, the underlying genetic mechanism
for EGFR overexpression is gene amplification [11].
However, molecular mechanisms for EGFR overex-
pression in the majority of cases are yet to be identi-
fied.
The aim of this study was to investigate the preva-
lence of EGFR overexpression, EGFR gene amplifi-
cation, and activating mutations in the tyrosine kinase
domain of this gene in a cohort of 47 MBCs. In addi-
tion, we studied the EGFR amplicon in detail in ten
cases by means of a comparative genomic hybridiza-
tion (CGH) array with a 0.6 Mb resolution on chromo-
some 7 to determine whether these gains were specific
to EGFR or whether they represented polysomy of
chromosome 7.
Materials and methods
Case selection
Cases of MBC were retrieved from the pathology
files of the Royal Marsden Hospital, London, UK;
IPATIMUP, Porto, Portugal; Laborato´rio Saloma˜o &
Zoppi, Sa˜o Paolo, Brazil; the Norwegian Radium
Hospital, Montebello, Norway; and the Brigham and
Women’s Hospital, Harvard Medical School, Boston,
MA, USA. This project was approved by the Local
Ethics Committees.
All cases were initially reviewed by the contribut-
ing authors, who used additional immunohistochem-
ical markers to corroborate the diagnosis. The cases
were centrally reviewed by three of the authors (JSRF,
FM, and FCS) on a multi-headed microscope and
classified according to previously described crite-
ria [11,13,22–28] into four groups: matrix-producing
breast carcinomas [26]; spindle cell carcinomas [25];
carcinomas with heterologous elements [24,27]; and
carcinomas with squamous differentiation [23,28].
Immunohistochemistry
EGFR overexpression was analysed immunohisto-
chemically using the monoclonal antibody 31G7
(Zymed) essentially as previously described [11].
EGFR immunostaining was analysed by three of the
authors (JSRF, FM, and FCS) on a multi-headed
microscope according to the Herceptest (Dako) scor-
ing system. Results on EGFR overexpression in 23
cases included in the present study have been previ-
ously described [11].
Chromogenic in situ hybridization (CISH)
CISH was performed using Spot-Light amplification
probes for EGFR (Zymed), according to the manufac-
turer’s protocol and as previously described [11]. As
the interpretation guidelines for the Spot-Light EGFR
amplification probe have been previously validated
[8], we did not use an α-satellite probe for chromo-
some 7. Signals were evaluated at ×400 and ×630 by
three of the authors (FM, SC, and JSR-F) and at least
60 cells were counted for the presence of the EGFR
probe. A given area was considered to be amplified for
EGFR when more than 50% of the neoplastic cells har-
boured (i) more than 5 signals per nuclei or (ii) large
gene copy clusters [8,11]. Results on EGFR amplifi-
cation in 23 cases included in the present study have
been previously described [11].
DNA extraction
Representative sections of each tumour were microdis-
sected with a sterile needle under a stereo microscope
to ensure a purity of at least 70% of neoplastic cells
as previously described [29].
Mutation analysis
Exon-specific primers were designed and DNA was
subjected to PCR amplification of exons 18, 19, 20,
and 21 of the EGFR gene. Primer sequences are shown
in Table 1. PCR reactions were performed in a final
volume of 25 µl, with the following composition: 1×
Buffer (Bioron, Germany); 1.25 mM MgCl2 (Bioron,
Germany) for exon 18 and 1.5 mM MgCl2 for exons
19, 20, and 21; 200 µM dNTPs (Fermentas, USA);
0.3 µM of each primer (MWG Biotech, Germany);
and 1 unit of Super Hot Taq Polymerase (Bioron,
Germany). Thirty-six cycles of denaturation (96 ◦C),
annealing (60 ◦C), and extension (72 ◦C) for 45 s each
were carried out in a thermocycler (BioRad, Hercules,
CA, USA).
PCR amplification was followed by SSCP analy-
sis. PCR products were mixed with an equal vol-
ume of denaturing loading buffer (98% formamide,
10 mM EDTA, 1 mg/ml bromophenol blue, and xylene
cyanol). After denaturing (95 ◦C for 10 min) and
quenching on ice, the mixtures were loaded onto 0.8×
MDE gel (Cambrex, Rockland, USA). Gels were run at
3 W, 20 ◦C for 20 h, silver-stained, and dried at 80 ◦C.
All samples were analysed in duplicate. Samples with
a SSCP pattern different from normal were directly
sequenced (Seqlab, Germany and Institute of Cancer
Table 1. Primers used for mutation analyses of the EGFR gene
Exon Primer sequence
PCR
product
size (bp)
Exon 18 Forward TGGGCCATGTCTGGCACTGC 283
Reverse ACAGCTTGCAAGGACTCTGG
Exon 19 Forward TCACTGGGCAGCATGTGGCA 241
Reverse CAGCTGCCAGACATGAGAAA
Exon 20 Forward CCTTCTGGCCACCATGCGAA 295
Reverse CGCATGTGAGGATCCTGGCT
Exon 21 Forward ATTCGGATGCAGAGCTTCTT 265
Reverse CCTGGTGTCAGGAAAATGCT
J Pathol 2006 (in press) DOI: 10.1002/path
Copyright  2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
EGFR gene amplification in metaplastic breast carcinomas
Research Sequencing Facility, UK) after purification
using MicroSpinTM S-400 HR Columns (Amersham
Biosciences, Piscataway, NJ, USA).
Direct sequencing
All cases with abnormal migration patterns on SSCP
analysis and an additional 16 randomly selected cases
were subjected to direct sequencing. Direct sequencing
was performed using the dideoxy chain termination
method and Big Dye technology (Applied Biosystems,
Foster City, CA, USA), using AmpliTaq Gold DNA
Polymerase. The primers were the same as those used
for SSCP analysis. Cycling conditions were as follows:
94 ◦C for 10 min; 41 cycles each of 30 s at 94 ◦C, 30 s
at 55 ◦C, and 1.5 min at 72 ◦C; followed by 7 min at
72 ◦C ending at 4 ◦C.
The products were run on a 3% agarose gel and
the DNA was extracted using the BIO 101 gene clean
II kit (QBiogene, Cambridge, UK) and then run on
an ABI 3100 or ABI 3700 sequencer (AB Applied
Biosystems). The results were analysed using 3100
data collection software. Sequencing was performed
twice for each sample to rule out the possibility of PCR
fidelity artefacts and was carried out in both directions.
Microarray-based comparative genomic
hybridization (CGH)
Ten cases, five with and five without known EGFR
amplifications (as defined by CISH), were subjected
to microarray-based CGH using the 4.6K 1.1.2 Break-
through Breast Cancer microarray-CGH platform. This
platform comprises approximately 4200 bacterial arti-
ficial chromosomes (BACs) spaced at approximately
1 Mb intervals throughout the genome. BAC clones
were spotted in triplicate onto Corning GAPSII-coated
glass slides (Corning, NY, USA). Labelling, hybridiza-
tion, and washes were carried out essentially as pre-
viously described [29]. Arrays were scanned with
a GenePix 4000A scanner (Axon Instruments, Inc,
Union City, CA, USA); fluorescence data were pro-
cessed with GenePix 4.1 image analysis software
(Axon Instruments, Inc).
Data analysis
The log2 ratios were normalized for spatial and
intensity-dependent biases using a two-dimensional
Loess local regression. The median of BAC clone
replicate spots was calculated after exclusion of exces-
sively flagged clones (>70% of samples). The median
log2 ratio for each clone was averaged across the
‘dye-swaps’. This left a final data set of 3664 clones
with unambiguous mapping information according to
the May 2004 build of the human genome (hg17),
of which 272 clones map to chromosome 7, con-
ferring a resolution of approximately 0.6 Mb. Data
were smoothed using a local polynomial adaptive
weights smoothing (aws) procedure for regression
problems with additive errors [30]. A categorical anal-
ysis was applied to the BACs after classifying them
as representing gain, loss, or no change according
to their smoothed log2 ratio values. Smoothed log2
ratio values below −0.09 were categorized as losses;
those above 0.09 as gains; and those in between as
unchanged. Data processing and analysis were carried
out in R 2.0.1 (http://www.r-project.org/) and Bio-
Conductor 1.5 (http://www.bioconductor.org/), mak-
ing extensive use of modified versions of the packages,
in particular aCGH, marray, and aws [29].
Statistical analysis
The Statview software package was used for all cal-
culations. Correlations between categorical variables
were performed using the chi-square test and Fisher’s
exact test. Correlations between continuous and cat-
egorical variables were performed with analysis of
variance (ANOVA).
Follow-up information was available for 38 out
of 47 patients, ranging from 5.5 to 124.3 months
(median = 36.9 months; mean = 51.9 months). Dis-
ease-free and overall survival was expressed as the
number of months from diagnosis to the occurrence
of an event (local recurrence/metastasis and disease-
related death, respectively). Cumulative survival prob-
abilities were calculated using the Kaplan–Meier
method. Differences between survival rates were tested
with the log-rank test. All tests were two-tailed, with
a confidence interval of 95%.
Results
EGFR overexpression (2+/3+) was observed in 32 of
47 cases (Table 2). A significant correlation between
EGFR overexpression and type of metaplastic ele-
ments was observed. Carcinomas with homologous
differentiation (ie spindle and squamous differen-
tiation) were more frequently positive for EGFR
than carcinomas with heterologous differentiation
(p < 0.0239, Fisher’s exact test).
EGFR amplification was found in 11 of 47 cases
(23%). All EGFR amplified cases were either spindle
cell carcinomas or carcinomas with squamous differ-
entiation (Figure 1). A statistically significant associ-
ation between EGFR gene amplification and type of
metaplastic elements was found: 31% of carcinomas
with homologous metaplasia versus 0% of carcino-
mas with heterologous elements (p < 0.0457, Fisher’s
exact test).
A significant direct correlation between EGFR
amplification and overexpression was found (p =
0.0094, Fisher’s exact test). Eleven amplified cases
showed EGFR overexpression, but EGFR overex-
pression was more pervasive. In fact, amplification
was the underlying mechanism of EGFR overexpres-
sion in 34% (11 of 32) of the cases. No association
between EGFR overexpression or amplification and
age, tumour size, lympho-vascular invasion and lymph
node metastasis was found (for all, p > 0.05).
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Table 2. Summary of correlations between EGFR gene copy numbers and overexpression and
clinico-pathological findings
EGFR IHC EGFR CISH
Parameter 0/1+ 2+/3+ p value No Amp Amp p value
Age 0.2124∗ 0.0933∗
≤50 5 18 8 15
>50 10 14 3 21
Size 0.5159∗ 0.4508∗
T1/T2 9 19 23 5
T3/T4 6 8 10 4
Type of metaplasia 0.0227∗ 0.0457∗
Homologous (n = 36) 8 28 25 11
Heterologous (n = 11) 7 4 11 0
Histological type 0.0316∗ 0.1701∗
Spcc (n = 13) 2 11 10 3
Squamous (n = 23) 6 17 15 8
Matrix (n = 8) 6 2 8 0
Heterologous (n = 3) 1 2 3 0
Lympho-vascular invasion‡ 0.4717∗ 0.4318†
Absent 3 13 14 2
Present 8 15 17 6
Lymph node metastasis§ 0.9999∗ 0.2152∗
Absent 7 16 3 20
Present 5 9 5 9
∗ Fisher’s exact test.
† Chi-square test.
‡ Information on lympho-vascular invasion was not available in eight cases.
§ Information on lymph node metastasis was not available in ten cases.
CISH = chromogenic in situ hybridization; heterologous = carcinoma with heterologous metaplasia; IHC =
immunohistochemistry; matrix = matrix-producing breast cancer; SpCC = spindle cell carcinoma; squamous =
carcinoma with squamous metaplasia.
Figure 1. Carcinoma with squamous metaplasia (A — H&E) showing 3+ immunoreactivity for EGFR (B — DAB/Harris’s
haematoxylin) and EGFR gene amplification in the form of large clusters of signals (C — CISH DAB/Harris’s haematoxylin). Note
the presence of stromal cells with one to two signals per nucleus (arrowheads). Spindle cell carcinoma composed of sheets of
spindle-shaped cells, with marked nuclear pleomorphism (D — H&E), displaying EGFR overexpression (3+) (E — DAB/Harris’s
haematoxylin) and gene amplification (F — CISH DAB/Harris’s haematoxylin). Inset: note the presence of more than ten signals
(EGFR gene copies), sometimes arranged in small clusters, in the nucleus of a pleomorphic neoplastic cell
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Table 3. Univariate disease-free survival (DFS) and overall survival (OS) of 47 patients with metaplastic breast
carcinomas
Disease-free survival Overall Survival
Parameter
Mean DFS
(months)
SE
(months) p value∗
Mean OS
(months)
SE
(months) p value∗
Age 0.1577 0.1274
≤50 75.5 10.7 89.4 11.0
>50 51.3 11.5 60.2 11.6
Size 0.0035 0.0108
T1/T2 82.9 10.1 92.2 9.03
T3/T4 32.9 10.1 49.7 15.82
Type of metaplasia 0.5608 0.5901
Homologous (n = 36) 60.9 9.4 75.3 9.85
Heterologous (n = 11) 61.2 10.9 93.1 14.59
Histological type 0.7336 0.8172
SpCC (n = 13) 46.9 10.6 64.0 12.7
Squamous (n = 23) 75.7 14.6 85.0 13.5
Matrix (n = 8) 55.2 12.8 84.9 18.8
Heterologous (n = 3) 37.3 0.0 37.3 0.0
Lympho-vascular invasion 0.0213 0.0012
Absent 89.6 11.93 109.9 7.73
Present 43.6 8.63 54.6 9.90
Lymph node metastasis 0.0007 0.0006
Absent 85.5 10.1 98.8 8.61
Present 33.0 9.9 45.0 13.42
EGFR IHC 0.3722 0.1943
Negative 69.9 11.23 100.0 13.10
Positive 58.5 9.91 68.4 9.65
EGFR CISH 0.0676 0.1047
No amplification 70.4 9.17 84.9 9.31
Amplification 34.6 11.23 49.2 15.22
∗ p values were calculated by the log-rank test.
Heterologous = carcinomawith heterologousmetaplasia; matrix = matrix-producing breast cancer; SpCC = spindle cell carcinoma;
squamous = carcinoma with squamous metaplasia.
Univariate survival analysis (Table 3) demonstrated
that size, lympho-vascular invasion, and lymph node
metastasis were significant predictors of disease-free
and overall survival. Tumours with EGFR overexpres-
sion and/or amplification showed a shorter disease-free
and overall survival; however, these associations failed
to reach statistically significant levels (Table 3).
Array CGH
In two cases (M4 and M6) with known amplifica-
tions as defined by CISH, the peak of the ampli-
con on 7p was restricted to 7p11.2, encompassing a
genomic region of 0.9 Mb (Figure 2), which was cov-
ered by BACs RP11-1013E24, RP11-81B20, RP11-
14K11, RP11-97P11, RP11-34J24, RP11-29K01, and
RP11-251I15. In three further cases, copy number
gains of 7p11.2-tel were observed. Interestingly, in
these cases the breakpoints were close to the EGFR
locus (Figure 2). M4 showed a high-level gain of
the EGFR locus, but the shoulders of the amplicon
comprised the chromosome 7 centromere. Microarray-
based CGH of the five cases without EGFR amplifi-
cation as defined by CISH confirmed the lack of 7p
genomic aberrations.
The minimal region of overlap in the five sam-
ples with EGFR gene copy number gain mapped to
7p11.2, spanning a region of 0.9 Mb (between 54.4
and 55.3 Mb on 7p). Interestingly, this region cor-
responded to the peaks observed in cases M4 and
M6, and encompasses three known genes, the Sec61
gamma subunit (SEC61G), EGFR, and LanC lan-
tibiotic synthetase component C-like 2 (LANCL2 )
(Figure 2).
Mutation analysis
Activating mutations in the tyrosine kinase domain
(exons 18, 19, 20, and 21) of EGFR were not identified
in 47 MBCs, either by SSCP or by direct sequenc-
ing. Intronic and silent mutations found in this series
are summarized in Table 4. The frequency of poly-
morphisms at codon 787 CAG to CAA (Gln/Gln) in
MBCs was 61.7% (29/47) and at codon 836 CGT to
CGC (Arg/Arg) 6.4% (3/47). No statistically signif-
icant correlation between the gene sequencing find-
ings (intronic mutations, silent mutations, and gene
polymorphisms) and clinico-pathological characteris-
tics or EGFR amplification or overexpression was
found (data not shown).
Discussion
In previous studies, we and others have demon-
strated that MBCs are part of the spectrum of basal-
like breast carcinomas [11,13,14,18,19,31,32]. One
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Figure 2. Ideogram and microarray CGH chromosome plots of chromosome 7, where the minimal region of amplification is
highlighted in grey. Log2 ratios are plotted on the x axis against each clone according to genomic location on the y axis. The
centromere is represented by a horizontal dotted line. Vertical dashed lines correspond to log2 ratios of 0.09 (green) and −0.09
(red). For details of genes mapping to the minimal region of amplification, see http://www.ensembl.org
Table 4. Summary of EGFR exon 18, 19, 20, and 21 sequencing
results
Histological
type
EGFR
IHC EGFR CISH Mutation
SpCC 3+ Not amplified Intron 18, IVS18 + 19G > A
Squamous 3+ Not amplified Exon 18, 2178G > A (V716V)
Exon 19, 2274A > G (E758E)
SpCC 3+ Amplified Intron 18, IVS18 + 19G > A
SpCC 3+ Amplified Exon 18, GAG > GAA (E690E)
Heterologous 3+ Not amplified Intron 18, IVS18 + 19G > A
Squamous 3+ Not amplified Exon 18, 2027A > G (E699E)
CISH = chromogenic in situ hybridization; heterologous = carcinoma
with heterologous elements; IHC = immunohistochemistry; SpCC =
spindle cell carcinoma; squamous = carcinoma with squamous
metaplasia.
of the defining features of basal-like breast cancer
[13,33] is EGFR overexpression, which is found in
up to approximately 60% of basal-like breast car-
cinomas, as defined by expression profiling analysis
[31,33]. MBCs frequently show EGFR overexpression
at both the immunohistochemical and the mRNA lev-
els [11,20,21].
In the present study, we have shown that ampli-
fication of EGFR is the underlying genetic mecha-
nism in 34% of MBCs with EGFR overexpression. Of
note, amplifications were significantly more frequently
observed in the group of tumours with squamous or
spindle cell metaplasia. These findings suggest that
MBCs with spindle or squamous metaplasia may be
part of the same entity. In fact, this group was histori-
cally classified under the term ‘metaplastic carcinoma
with homologous elements’ [27]. In addition, it is
well known that foci of squamous metaplasia are fre-
quently found in spindle cell carcinomas and spindle
cell metaplasia is not rare in breast carcinomas with
squamous metaplasia [24,25,28,34,35]. Furthermore,
in other anatomical sites, spindle cell carcinomas are
considered variants of squamous cell carcinomas [36].
Microarray-based CGH revealed the complex nature
of the 7p11.2 amplicon. Interestingly, the minimal
region of amplification encompasses only three genes:
SEC61G, LANCL2, and EGFR. SEC61G encodes the
gamma-subunit protein of the Sec61 complex, which
is part of the protein translocation apparatus of the
endoplasmic reticulum (ER) membrane [37]; there is
J Pathol 2006 (in press) DOI: 10.1002/path
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currently no evidence to support an oncogenic role for
this gene. The LANCL2 gene encodes the lanthionine
synthetase component C (LanC)-like protein 2, also
known as testis adriamycin sensitivity protein, which
is a member of the eukaryotic LanC-like protein
family. This gene is co-amplified and overexpressed
with EGFR in 20% of all glioblastomas [38]. Although
there is no evidence to suggest that LANCL2 may be
an oncogene candidate, this gene is reported to play
a role in increasing cellular sensitivity to adriamycin
by decreasing the expression of P-glycoprotein in
cell line models [39]. On the other hand, there are
several lines of evidence to suggest that EGFR is
the most likely oncogene candidate in this amplicon,
given that all cases with EGFR amplification showed
overexpression and that its oncogenic properties have
been extensively characterized in different tumour
types [1].
As EGFR overexpression is more prevalent than
EGFR gene amplification, we sought to investigate
whether activating EGFR gene mutations would con-
stitute an alternative mechanism for EGFR overexpres-
sion. In fact, activating EGFR mutations have been
reported to correlate with EGFR overexpression in
human tumours [40]. We could not identify activating
mutations in the tyrosine kinase domain of 47 MBCs.
Our results are in agreement with previous studies
demonstrating the lack of EGFR activating mutations
in breast cancer [8]. In contrast, Weber et al [41] found
EGFR gene mutations in neoplastic cells of six of 72
breast carcinomas. Surprisingly, in that study, muta-
tions were found in both stromal and neoplastic cells
[41]. These differences may be explained by the dif-
ferent histological types analysed and gene sequencing
approaches used. Furthermore, in the present study,
only the EGFR tyrosine kinase domain was analysed.
Although exons 18–21 are the hot-spot region for
EGFR gain-of-function mutations [1,5,12], activating
mutations in other domains of the gene cannot be
excluded.
The mechanism for EGFR overexpression in the
majority of MBCs remains to be identified. It is likely
that, in the majority of cases, EGFR up-regulation hap-
pens at the transcriptional level [42]. Given that this
gene is consistently expressed in normal myoepithe-
lial cells [43] and tumours with basal and/or myoep-
ithelial differentiation [13,33,44,45], one could argue
that EGFR overexpression in MBCs would consti-
tute only maintenance of a myoepithelial phenotype
or would be part of a transcriptomic programme of
myoepithelial/‘basal-like’ differentiation. In fact, there
is evidence to suggest that EGFR expression may be
regulated at the transcriptional level [46,47]. Recent
in vitro studies with human mammary epithelial cells
(HMECs) have demonstrated that up-regulation of the
transcription factor Y-box-binding protein 1 induces
EGFR overexpression and ligand-independent activa-
tion of the EGFR pathway [46]. However, the preva-
lence of this mechanism in human breast cancer is yet
to be accurately determined.
The intron 1 CA repeat amplification, which has
been reported in ∼6% of invasive breast cancer [42],
has also been postulated as an alternative genetic
mechanism that may lead to EGFR overexpression.
Although intron 1 CA repeat amplification does not
always correlate with amplification of the whole EGFR
gene [42], as defined by fluorescent in situ hybridiza-
tion, it shows a significant correlation with EGFR
overexpression and may be the underlying genetic
mechanism driving EGFR expression in approximately
19% of the cases [42]. Another mechanism would
be the presence of a type III EGF deletion-mutant
receptor, known as EGFRvIII, which is character-
ized by the deletion of exons 2–7 in the EGFR
mRNA, leading to deletion of 801 bp within the
extracellular domain of the EGFR gene and caus-
ing an in-frame truncation of the normal EGFR pro-
tein [48,49]. EGFRvIII is constitutively activated and
is reported to induce increased colony formation,
anchorage-dependent and -independent growth, and
greater tumourigenicity when transfected into MCF-7
cells [49]. The presence of EGFRvIII in breast can-
cer was originally thought to be very common (78%)
[50]; however, more recent and better-designed stud-
ies have failed to identify this EGFR variant in breast
cancers and breast cancer cell lines [51]. Further stud-
ies testing these alternative mechanisms as the drivers
of EGFR overexpression in metaplastic breast cancer
are warranted.
Given that (i) MBCs are reported not to respond to
conventional chemo- and hormone therapy, (ii) tum-
ours with EGFR amplifications are reported to respond
to tyrosine kinase inhibitors [6,52,53], and (iii) a
subset of basal-like breast carcinomas (metaplastic
breast carcinomas) harbour these amplifications [11],
studies addressing the efficacy of EGFR tyrosine
kinase inhibitors in patients with EGFR amplification
are warranted. As EGFR activating mutations in
the tyrosine kinase domain are remarkably rare in
breast carcinomas [8,41], our findings also suggest
that EGFR gene copy number and other indicators
of EGFR therapy effectiveness [12,53–57], rather
than EGFR mutation analysis, should be assessed in
larger cohorts of basal-like tumours to define patient
eligibility for inclusion in clinical trials assessing the
efficacy of EGFR tyrosine kinase inhibitors in breast
cancer.
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